January 2025 – LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading Pharmaceutical technology company, is proud to announces ...
ANDERNACH, GERMANY - Newsaktuell - 14 January 2025 - LTS LOHMANN Therapie-Systeme AG (LTS), a leading <a target=_blank href= ...
The University of Queensland's BASE facility – within the Australian Institute for Bioengineering and Nanotechnology (AIBN) – and Brisbane-based biotechnology company Vaxxas have been announced as ...
For CIOs leading enterprise transformations, portfolio health isn't just an operational indicator — it's a real-time pulse on ...
From di chewing gum coloured lakes for Australia to di solar powered safari camp for Botswana, dis na BBC tori pipo top ...
Much of the foreign policy discourse this week has focused on President-elect Donald Trump. He continued to call Canada the “51st state” and again called for taking ownership of the Panama Canal; he ...
Once crowned among Europe's most eligible bachelors, Prince Ludwig of Bavaria welcomed Prince Rupprecht with his human rights ...
CES 2025 showcased everything from artificial intelligence-powered sleep aids to smart ear-cleaning devices. Kurt the CyberGuy has the details.
Get Fit in Style! With the surge of innovative fitness trackers in 2025, staying on top of your fitness game has never been ...
PopVax awarded $2M for its patch-delivered mRNA influenza vaccine in collaboration with LTS Lohmann as part of BARDA’s Patch Forward Prize.
Vaxxas Named Stage Winner of United States’ BARDA Prize to Advance Microarray Patches for Vaccination ...